Top

Published in:

12-12-2023 | Acute Lymphoblastic Leukemia | Original Article

Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation

Authors: Jun Nukui, Takayoshi Tachibana, Takuya Miyazaki, Masatsugu Tanaka, Kenji Matsumoto, Yoshimi Ishii, Ayumi Numata, Yuki Nakajima, Ayako Matsumura, Taisei Suzuki, Akihiko Izumi, Natsuki Hirose, Koji Yamamoto, Maki Hagihara, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima

Published in: International Journal of Hematology | Issue 1/2024

Abstract

The clinical implications of recipient bone marrow nucleated cell count (NCC) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unknown. We conducted a multicenter retrospective study to evaluate the clinical significance of bone marrow NCC prior to allo-HSCT in patients with acute lymphoblastic leukemia. Patients who were in remission and underwent the initial allo-HSCT were included and stratified into high- and low-NCC groups using an NCC of 10 × 10⁴/µL as the cut-off. The 3-year overall survival (OS), non-relapse mortality (NRM), and relapse rates for the high- and low-NCC groups were 51.2 vs. 84.5% (p < 0.001), 27.5 vs. 6.5% (p < 0.001), and 31.1 vs. 24.4% (p = 0.322), respectively. The high-NCC group had significantly poorer OS and higher NRM when compared with the low-NCC group. In summary, high recipient bone marrow NCC is associated with higher NRM and lower OS following allo-HSCT.

Available only for authorised users

Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC, International Council for Standardization in Hematology. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 2008;30:349–64. https://doi.org/10.1111/j.1751-553X.2008.01100.x.CrossRefPubMed

Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930–4. https://doi.org/10.1182/blood-2002-01-0339.CrossRefPubMed

Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, et al. Outcomes and prognostic factors for patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter analysis. Biol Blood Marrow Transplant. 2020;26:998–1004. https://doi.org/10.1016/j.bbmt.2020.01.007.CrossRefPubMed

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. ref. 4th ed. IARC: Lyon; 2017.

Hoelzer D, Gökbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol. 2000;27:540–59.PubMed

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9. https://doi.org/10.1016/j.bbmt.2008.12.497.CrossRefPubMedPubMedCentral

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMed

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17. https://doi.org/10.1016/0002-9343(80)90380-0.CrossRefPubMed

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.CrossRefPubMed

10.

Streck BP, Naufal G, Carrum G, Hill L, Heslop HE, Ramos CA, et al. Demographic and clinical donor characteristics as predictors of total nucleated cell concentrations in harvested marrow products. Transplant Cell Ther. 2021;27(785):e1-6. https://doi.org/10.1016/j.jtct.2021.05.021.CrossRef

11.

Ince UE, Ileri T, Dogu F, Ates C, Cakmakli H, Dalva K, et al. The impact of donor age and sex on the nucleated cell count and CD34 count in healthy bone marrow donors. Pediatr Transplant. 2015;19(4):385–90. https://doi.org/10.1111/petr.12453.CrossRefPubMed

12.

Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, et al. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50:559–65. https://doi.org/10.1038/bmt.2014.293.CrossRefPubMed

13.

Gupta A, Punatar S, Gawande J, Mathew L, Bagal B, Kannan S, et al. Risk factors, pattern and clinical outcome of acute graft versus host disease in acute leukemia patients undergoing allogeneic stem cell transplant. Indian J Hematol Blood Transfus. 2015;31:404–12. https://doi.org/10.1007/s12288-014-0499-5.CrossRefPubMedPubMedCentral

14.

Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transplant. 2016;22:134–40. https://doi.org/10.1016/j.bbmt.2015.09.008.CrossRefPubMed

15.

Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–9. https://doi.org/10.1182/blood-2010-08-302109.CrossRefPubMedPubMedCentral

16.

Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113:1631–8. https://doi.org/10.1182/blood-2008-03-147041.CrossRefPubMed

17.

Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221–34. https://doi.org/10.3109/10428190009087014.CrossRefPubMed

18.

Kawashima N, Terakura S, Nishiwaki S, Koyama D, Ozawa Y, Ito M, et al. Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation. Bone Marrow Transplant. 2017;52:1164–70. https://doi.org/10.1038/bmt.2017.58.CrossRefPubMed

Title: Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation
Authors: Jun Nukui
Takayoshi Tachibana
Takuya Miyazaki
Masatsugu Tanaka
Kenji Matsumoto
Yoshimi Ishii
Ayumi Numata
Yuki Nakajima
Ayako Matsumura
Taisei Suzuki
Akihiko Izumi
Natsuki Hirose
Koji Yamamoto
Maki Hagihara
Shin Fujisawa
Heiwa Kanamori
Hideaki Nakajima
Publication date: 12-12-2023
Publisher: Springer Nature Singapore
Keywords: Acute Lymphoblastic Leukemia
Graft-Versus-Host Disease
Graft-Versus-Host Disease
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: International Journal of Hematology / Issue 1/2024
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-023-03688-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition

Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis

Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer